查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1857907

局部性节段性肾小球硬化症市场按药物类别、分期、最终用户和患者类型划分 - 全球预测 2025-2032

Focal Segmental Glomerulosclerosis Market by Drug Class, Stage, End-Use, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，局部节段性肾丝球硬化症市场规模将达到 36.9 亿美元，复合年增长率为 8.07%。

关键市场统计数据
基准年 2024 19.8亿美元
预计年份：2025年 21.3亿美元
预测年份 2032 36.9亿美元
复合年增长率 (%) 8.07%

本书以临床为导向，介绍局部节段性肾丝球硬化症，重点阐述诊断的复杂性、治疗重点以及如何为相关人员建立多学科诊疗路径。

局部节段性肾小球硬化症 (FSGS) 是卫星群的总称，其特征为足细胞损伤、肾小球内节段性硬化和进行性蛋白尿，常导致慢性肾功能障碍。临床上，FSGS 的病因多种多样，从特发性机製到继发性病因，包括感染疾病、药物、肾单位缺失的适应性反应以及基因突变等。因此，FSGS 的诊断需要综合考虑临床症状、实验室检查（包括蛋白尿和生物标记的定量）以及切片检查的组织病理学确诊。

目前的临床治疗重点在于尽可能找出并解决潜在原因，同时采取支持性措施保护肾臟。血压控制和透过调节肾素-血管收缩素系统来减少蛋白尿是基础治疗。糖皮质激素治疗仍然是许多患者的主要治疗手段，尤其是在对荷尔蒙敏感的疾病中；然而，不利事件和疗效差异凸显了开发其他治疗策略的必要性。在整个医疗保健系统中，整合肾臟病学、病理学、遗传学及相关专科的多学科诊疗模式对于优化治疗效果、预防疾病进展以及控制水肿、高血脂症和血栓风险等併发症的重要性日益凸显。

随着该领域的发展，相关人员临着科学发现、不断演变的法规和以病人为中心的期望之间动态的相互作用。本导言概述了局部节段性肾小球硬化症（FSGS）的临床和营运现状，重点强调了将诊断的复杂性、治疗重点和研究进展与日常实践的可行路径相结合的必要性。

局部节段性肾丝球硬化症的临床、诊断和转化医学方面的变革性转变正在重塑治疗策略、试验设计和多学科护理模式。

局部节段性肾丝球硬化症的治疗模式正在经历一场变革性的转变，这主要得益于科学、技术和医疗服务三方力量的融合。在生物学层面，基因组学和分子病理学的进步揭示了不同的机制亚型，使得治疗方法。这些分子层面的发现加速了潜在的类固醇替代疗法和缓解疾病标靶的识别，并重新调整了临床试验的入组标准，使其更加关註生物学同质性较高的患者群体。

同时，从精细化的免疫组化检测、数位病理学到辅助病变分类的机器学习演算法等诊断工具的创新，正在提高诊断的一致性并降低观察者间的差异。这些工具支持更早期、更准确的诊断，进而指导治疗顺序和监测策略。临床试验设计也在同步发展，改良的方案、富含生物标记的队列以及患者报告结局终点等，正成为实证医学范式中日益重要的特征。

医疗保健系统和支付方的动态变化也在再形成决策路径。随着治疗方法选择的增多，其价值、疗效持久性和实际疗效正受到越来越多的检视。医疗服务提供者正在采取整合式照护路径，强调肾臟保护、併发症管理和照护协调，以降低后续併发症的发生率。病患权益倡导和数位化参与提高了疾病认知度和临床试验参与率，学术中心、生物技术创新者和诊断公司之间的合作正在推动转化医学的进步。这些转变共同营造了一种局面，在这种局面下，精准医疗和主导医学的应用将对患者的治疗结果产生长期影响。

一项基于证据的评估，旨在了解美国在 2025 年实施的关税政策如何影响局部节段性肾小球硬化症管理的供应链、筹资策略和临床连续性。

美国2025年关税的实施对局部节段性肾丝球硬化症（FSGS）生态系统产生了多方面的影响，波及供应链物流、筹资策略和治疗经济等各个环节。製药公司和经销商面临进口活性原料药和特殊成分的短期成本调整，迫使许多机构重新评估筹资策略和库存缓衝。依赖国际供应链取得关键治疗药物、诊断试剂、切片检查处理材料等的医院和诊所不得不调整其采购和库存管理方式，以维持医疗服务的连续性，避免治疗流程中断。

为因应不断上涨的进口相关成本，多个相关人员加快了本地化生产和供应商多元化的步伐。这项转变促成了更具策略性的采购伙伴关係，并更加重视区域製造中心，以减轻关税和物流不确定性的影响。同时，支付方和采购集团也加强了对采购成本的审查，这影响了处方谈判和合约签订方式。政策因应措施和机构合约也随之调整，优先考虑供应安全和可预测的定价机制，这与旨在保障基本医疗供应链的国内製造奖励和公私合作的长期讨论相一致。

在临床方面，对病患的直接影响主要集中在采购替代风险和系统调整期间可能带来的行政负担。然而，从长远来看，这为提升供应韧性、加强临床医生、供应链领导者和製造商之间的伙伴关係提供了机会。这些调整强调采购透明度、加快供应商资质认证流程以及投资于生产冗余，所有这些都有助于在不断变化的贸易环境下，为FSGS治疗的持续进行奠定更坚实的基础。

深度分割智能揭示了药物类别、疾病阶段、治疗环境和患者属性如何共同影响局部节段性肾小球硬化症（FSGS）的治疗路径和实证医学优先事项。

分段分析为理解局部节段性肾小球硬化症 (FSGS) 的治疗方法选择和护理路径提供了至关重要的细节，每个维度都揭示了不同的临床和商业考虑。药物类别包括血管收缩素酶抑制剂、血管收缩素受体阻断剂和糖皮质激素，这反映了它们在肾臟保护、减少蛋白尿和免疫调节方面的不同作用。原发性疾病与次发性疾病的区分突显了基于疾病分期的病因和治疗策略的差异。原发性疾病通常需要免疫抑制和标靶治疗，而次发性疾病则需要在保护肾臟的同时治疗原发性疾病。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 透过生物标记主导的FSGS患者分层进行标靶治疗，推进精准医疗
  • 对基因编辑技术的投资不断增加，重点在于与FSGS易感性相关的APOL1基因突变。
  • 开发新型内皮素受体拮抗剂，这些拮抗剂在FSGS的临床试验中显示出肾臟保护作用。
  • 扩展以患者为中心的数位健康平台，用于远端监测和管理FSGS进展
  • 加强学术界与生技公司之间的合作，加速早期局部性节段性肾丝球硬化症（FSGS）药物研发进程。
  • 儿童局部节段性肾丝球硬化症（FSGS）盛行率的增加推动了针对特定年龄层治疗方案的需求。
  • 真实世界临床试验的出现，检验新型FSGS治疗的长期安全性和有效性。
  • FDA突破性疗法认定加速创新FSGS生物製药和小分子药物的监管审批路径
  • 采用脂质体药物传递系统增强肾臟标靶性并降低治疗局部性节段性肾小球硬化症（FSGS）的脱靶毒性。
  • 合约研究机构 (CRO) 与製药公司之间策略伙伴关係的激增，旨在优化局部节段性肾小球硬化症 (FSGS) 临床试验

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的局部节段性肾丝球硬化症市场

  • 血管收缩素酶抑制剂
  • 血管收缩素受体阻断剂
  • 皮质类固醇

9. 局部节段性肾丝球硬化症市场（依阶段划分）

  • 基本的
  • 次发性

10. 依最终用途分類的局部节段性肾丝球硬化症市场

  • 诊所
  • 医院

11. 依病患类型分類的局部节段性肾丝球硬化症市场

  • 成人
  • 孩子们

12. 区域性局部性节段性肾丝球硬化症市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 局部节段性肾丝球硬化症市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国局灶节段性肾丝球硬化症市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Alkem Laboratories Ltd.
    • Bristol Myers Squibb Company
    • Certa Therapeutics Pty Ltd.
    • Cipla Ltd.
    • CMG Biotech Pvt. Ltd.
    • Dr Reddy's Laboratories Ltd.
    • Fresenius Kabi Pvt. Ltd.
    • GSK PLC
    • Hikma Pharmaceuticals PLC
    • Intas Pharmaceuticals Ltd.
    • Lupin Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Otsuka Pharmaceutical Co., Ltd
    • Pfizer, Inc.
    • Sanofi SA
    • Travere Therapeutics, Inc.
    • Vera Therapeutics Inc.
Product Code: MRR-C002B1C994EF

The Focal Segmental Glomerulosclerosis Market is projected to grow by USD 3.69 billion at a CAGR of 8.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.98 billion
Estimated Year [2025] USD 2.13 billion
Forecast Year [2032] USD 3.69 billion
CAGR (%) 8.07%

A clinically oriented introduction to focal segmental glomerulosclerosis that frames diagnostic complexity, therapeutic priorities, and multidisciplinary care pathways for stakeholders

Focal segmental glomerulosclerosis (FSGS) represents a constellation of clinicopathologic processes characterized by podocyte injury, segmental sclerosis within glomeruli, and progressive proteinuria that frequently culminates in chronic kidney impairment. Clinicians encounter FSGS across a spectrum of etiologies ranging from idiopathic mechanisms to secondary causes tied to infections, medications, adaptive responses to reduced nephron mass, and genetic variants. Consequently, diagnosis demands a synthesis of clinical presentation, laboratory assessment including proteinuria quantification and biomarkers when available, and histopathologic confirmation through renal biopsy, where podocyte effacement and segmental scarring remain key diagnostic hallmarks.

Current clinical management hinges on addressing the underlying cause where identifiable while applying supportive renal protective measures. Blood pressure control and mitigation of proteinuria through renin-angiotensin system modulation constitute foundational care. Corticosteroid therapy continues to play a central role for many patients, particularly in steroid-responsive disease, yet the adverse event profile and variable response rates underscore the need for additional therapeutic strategies. Across health systems, multidisciplinary care models that integrate nephrology, pathology, genetics, and allied specialties are increasingly pivotal to optimize outcomes, reduce progression, and manage complications such as edema, hyperlipidemia, and thrombotic risk.

As the field advances, stakeholders face a dynamic interplay of scientific discovery, regulatory evolution, and patient-centered expectations. This introduction frames the clinical and operational landscape of FSGS, highlighting diagnostic complexity, therapeutic priorities, and the imperative to align research momentum with pragmatic pathways for adoption in routine care.

Transformative clinical, diagnostic, and translational shifts reshaping therapeutic strategies, trial designs, and multidisciplinary care models in focal segmental glomerulosclerosis

The landscape of focal segmental glomerulosclerosis is undergoing transformative shifts driven by converging scientific, technological, and care-delivery forces. At the biological level, advances in genomics and molecular pathology have clarified distinct mechanistic subtypes, enabling a move away from one-size-fits-all approaches toward mechanism-informed therapeutic selection. This molecular resolution has accelerated the identification of targets that promise steroid-sparing or disease-modifying potential and has reframed trial enrollment criteria to focus on biologically homogeneous cohorts.

Concurrently, innovations in diagnostic modalities-from refined immunohistochemical panels to digital pathology and machine-learning algorithms that assist in lesion classification-are improving diagnostic consistency and reducing interobserver variability. These tools support earlier and more precise diagnosis, which in turn informs treatment sequencing and monitoring strategies. Trial design has evolved in parallel, with adaptive protocols, biomarker-enriched cohorts, and patient-reported outcome endpoints becoming more prominent features in evidence generation frameworks.

Health-system and payer dynamics are also reshaping decision pathways. As therapeutic options broaden, there is increased scrutiny on value, durability of response, and real-world effectiveness. Providers are adopting integrated care pathways that emphasize nephroprotection, co-morbidity management, and care coordination to reduce downstream morbidity. Patient advocacy and digital engagement have elevated disease awareness and trial participation, while collaborations among academic centers, biotech innovators, and diagnostic firms are catalyzing translational progress. Together, these shifts are creating a landscape in which precision therapeutics and evidence-driven adoption determine long-term impact on patient outcomes.

An evidence-based assessment of how United States tariff policies introduced in 2025 influenced supply chains, procurement strategies, and clinical continuity for focal segmental glomerulosclerosis management

The imposition of United States tariffs in 2025 exerts a multifaceted influence on the FSGS ecosystem, with reverberations across supply chain logistics, procurement strategies, and the economics of care. Pharmaceutical manufacturers and distributors confronted short-term adjustments to costs for imported active pharmaceutical ingredients and specialty components, prompting many organizations to reassess sourcing strategies and inventory buffers. Hospitals and clinics that rely on international supply chains for key therapeutics, diagnostic reagents, and biopsy processing materials have had to adapt purchasing and inventory management practices to maintain continuity of care and avoid disruptions in treatment pathways.

In response to increased import-related costs, several stakeholders accelerated initiatives to localize aspects of production and to diversify supplier bases. This reorientation has translated into more strategic procurement partnerships and increased interest in regional manufacturing hubs to mitigate tariff exposure and logistical volatility. At the same time, payers and purchasing groups intensified scrutiny of acquisition costs, which has influenced formulary negotiations and contracting approaches. Policy responses and institutional contracting evolved to prioritize supply security and predictable pricing mechanisms, dovetailing with longer-term conversations about domestic manufacturing incentives and public-private collaboration to secure essential medical supply chains.

Clinically, the immediate patient-facing impact centered on procurement-driven substitution risks and potential administrative burdens while systems adjusted. However, the longer-term landscape revealed opportunities for improved supply resilience and strengthened partnerships between clinicians, supply chain leaders, and manufacturers. These adaptations emphasized transparency in sourcing, the acceleration of supplier qualification processes, and investments in manufacturing redundancy, all of which contribute to a more resilient foundation for delivering uninterrupted FSGS care under shifting trade conditions.

Deep segmentation intelligence revealing how drug class, disease stage, care setting, and patient demographics converge to shape therapeutic pathways and evidence priorities in FSGS

Segmentation analysis provides essential granularity for understanding therapeutic choices and care pathways in FSGS, and each axis illuminates distinct clinical and commercial considerations. Based on Drug Class, market analysis distinguishes between Angiotensin Enzyme Inhibitors, Angiotensin Receptor Blockers, and Corticosteroids, reflecting differential roles in renoprotection, proteinuria reduction, and immunomodulation; angiotensin-modulating agents remain core to supportive therapy, while corticosteroids address immune-mediated processes but carry trade-offs related to safety and tolerability. Based on Stage, the dichotomy of Primary and Secondary disease highlights diverging etiologies and management strategies; primary disease often prompts immunosuppression and targeted interventions, whereas secondary forms demand treatment of the inciting condition alongside renal protection.

Based on End-Use, settings of care across Clinics and Hospitals shape diagnostic workflows and treatment delivery; outpatient clinics play a central role in longitudinal monitoring and chronic therapy management, whereas hospitals are pivotal for acute presentations, biopsy procedures, and initiation of intensive immunosuppressive regimens. Based on Patient Type, adults and pediatric populations present distinct clinical trajectories, dosing considerations, and long-term care needs, with pediatric cohorts requiring particular attention to growth, developmental impacts of treatment, and genetic etiologies that may influence therapeutic selection.

Integrating these segmentation lenses reveals cross-cutting imperatives: therapeutics must demonstrate favorable benefit-risk profiles across age groups and disease stages, diagnostic and treatment pathways must be adaptable to both clinic and hospital environments, and evidence generation should be stratified to address etiologic heterogeneity. Stakeholders that align development programs, clinical trial design, and commercial strategies with these segmentation realities are positioned to address unmet needs more precisely and to facilitate adoption in the appropriate care settings.

Comprehensive regional analysis highlighting divergent diagnostic capabilities, clinical research ecosystems, and access dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a pronounced influence on how FSGS is diagnosed, treated, and researched, and recognizing these differences is essential for global strategy. In the Americas the healthcare landscape features advanced nephrology networks, strong transplant programs, and concentrated centers of clinical research that drive protocol development and trial participation; reimbursement frameworks and payer expectations in this region often shape pricing models and access pathways for new therapies. Europe, Middle East & Africa displays substantial heterogeneity across health systems, with well-resourced markets offering rapid adoption in specialist centers while other locations contend with limited diagnostic capacity, constrained access to biopsy services, and variable reimbursement pathways that affect treatment availability.

In Asia-Pacific the combination of large patient populations, expanding clinical research capacity, and diverse regulatory environments creates both opportunity and complexity; several jurisdictions are investing heavily in diagnostic infrastructure and precision-medicine initiatives, which supports enrollment in biomarker-driven studies and accelerates local evidence generation. Across regions, differences in genetic backgrounds, environmental exposures, and patterns of secondary causes influence epidemiology and clinical presentation, necessitating region-specific approaches to guideline development, trial design, and patient engagement. Moreover, regional supply chain configurations and procurement practices affect the availability and continuity of specialized therapies and diagnostic reagents, underscoring the importance of tailored commercialization plans and partnerships that reflect local regulatory, reimbursement, and care-delivery realities.

Strategic corporate behaviors and partnership models driving therapeutic innovation, diagnostic integration, and payer alignment to support differentiated approaches in focal segmental glomerulosclerosis

Company strategies in the FSGS domain reflect a blend of clinical ambition and pragmatic alignment with regulatory and payer expectations. Innovators are prioritizing pipeline programs that target molecularly defined mechanisms with the potential to alter disease course or reduce reliance on broad immunosuppression. These programs often pair therapeutic development with companion diagnostics or biomarker strategies to enable more precise patient selection and to demonstrate differentiated value in clinical trials. At the same time, established pharmaceutical firms are leveraging scale and distribution networks to optimize access for existing standard-of-care therapies while exploring combination approaches or label expansions that address unmet subpopulations.

Strategic partnerships are common, with biopharma collaborating with diagnostic developers, academic centers, and contract research organizations to accelerate translational milestones and streamline trial execution. Commercial strategies emphasize early engagement with payers and health technology assessment bodies to clarify evidence requirements and to design post-approval evidence-generation plans. Additionally, manufacturers are investing in patient support programs, digital adherence tools, and provider education to facilitate optimal use and monitoring of therapies. Competitive dynamics also reflect the role of generics and established antihypertensive agents within supportive care, necessitating clear positioning and outcomes data for novel interventions to justify differentiated adoption in clinical practice.

Actionable and integrated recommendations for industry leaders to align development, diagnostics, payer engagement, and supply resilience for optimized FSGS program execution

Industry leaders should adopt a set of actionable priorities to navigate the evolving FSGS landscape and to translate scientific advances into improved patient outcomes. First, align clinical development programs with mechanism-based patient stratification to increase the likelihood of meaningful clinical responses and to streamline regulatory discussions. Second, pair therapeutic programs with robust biomarker and diagnostic strategies to facilitate patient selection, monitoring, and value demonstration in payer dialogues. Third, invest in decentralized and hybrid trial designs that lower participation barriers and that capture real-world effectiveness across diverse populations.

Fourth, strengthen collaborations with nephrology centers of excellence and patient advocacy groups to enhance recruitment, capture patient-reported outcomes, and ensure that trial endpoints reflect clinically meaningful benefits. Fifth, proactively engage payers and health technology assessment bodies early in the development cycle to define acceptable evidence thresholds and to design post-approval evidence-generation that supports reimbursement. Sixth, implement supply-chain resilience measures, including diversified sourcing and regional manufacturing partnerships, to mitigate risks from trade policy shifts and logistical disruptions.

Seventh, develop comprehensive education and support programs for clinicians and patients to optimize initiation, monitoring, and adherence to novel regimens, with particular attention to pediatric considerations and comorbidity management. Eighth, incorporate health-economic analyses and real-world evidence plans into launch strategies to demonstrate long-term value to stakeholders. By executing this integrated set of actions, industry teams can reduce adoption friction, enhance patient benefit, and create durable pathways for sustainable therapeutic uptake.

A rigorous multi-method research methodology combining clinical literature, trial registry mapping, expert interviews, and real-world evidence synthesis with transparent quality controls

This analysis synthesized a multi-source research methodology to ensure robustness, transparency, and replicability in deriving strategic insights. The approach combined systematic literature review of peer-reviewed clinical and translational studies, analysis of public regulatory documents and clinical trial registries to map evidence generation trends, and structured interviews with nephrology clinicians, pathology experts, and health-system leaders to validate key assumptions and operational realities. Real-world evidence inputs-including aggregated observational data, registries, and claims-based analyses where publicly available-were triangulated with clinical trial findings to contextualize treatment patterns and diagnostic utilization.

The research also incorporated landscape mapping of therapeutic candidates, diagnostics, and service delivery models, supported by analysis of reimbursement frameworks and procurement practices across major jurisdictions. Quality assurance processes included independent review by clinical subject-matter experts, consistency checks across data sources, and transparent documentation of inclusion criteria and evidence limitations. Where gaps in public evidence existed, insights relied on expert consensus and scenario-based reasoning, with clear annotation of inferential assumptions. Limitations to note include variability in biopsy utilization and diagnostic coding practices across systems, and the evolving nature of therapeutic pipelines that may outpace published evidence; these factors were addressed through sensitivity in interpretation and emphasis on mechanism-driven trends rather than quantitative forecasts.

A concise, integrative conclusion summarizing how scientific advances, diagnostic precision, and systemic resilience will determine the future care pathways for FSGS

Focal segmental glomerulosclerosis occupies a complex intersection of unmet clinical need, advancing scientific understanding, and shifting healthcare dynamics. Diagnostic precision and mechanistic stratification are redefining how clinicians conceptualize FSGS subtypes, and this evolution enables more targeted therapeutic approaches that may reduce reliance on broadly immunosuppressive regimens. Concurrent innovations in diagnostics, trial design, and care delivery are facilitating earlier and more individualized interventions, while supply-chain and policy developments underscore the importance of operational resilience.

For stakeholders across the ecosystem, the imperative is to translate mechanistic insights into pragmatic clinical pathways that account for heterogeneity in patient populations, care settings, and regional systems. Strategic alignment among developers, payers, providers, and patient communities-anchored by robust evidence generation and clear value communication-will determine which innovations reach routine practice and which remain constrained to niche settings. Ultimately, the trajectory for FSGS care depends on coordinated efforts to couple scientific advances with implementation strategies that prioritize patient benefit, equitable access, and long-term sustainability within health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advances in precision medicine with biomarker-driven FSGS patient stratification for targeted therapies
  • 5.2. Rising investment in gene editing technologies focusing on APOL1 gene variants associated with FSGS susceptibility
  • 5.3. Development of novel endothelin receptor antagonists demonstrating nephroprotective effects in FSGS clinical studies
  • 5.4. Expansion of patient-centric digital health platforms for remote monitoring and management of FSGS progression
  • 5.5. Increasing collaboration between academia and biotech firms to accelerate early-stage FSGS drug discovery pipelines
  • 5.6. Growing prevalence of FSGS in paediatric populations driving demand for age-specific therapeutic formulations
  • 5.7. Emergence of real-world evidence studies to validate long-term safety and efficacy of emerging FSGS treatments
  • 5.8. FDA breakthrough therapy designations accelerating regulatory paths for innovative FSGS biologics and small molecules
  • 5.9. Adoption of liposomal drug delivery systems to enhance renal targeting and reduce off-target toxicity in FSGS therapies
  • 5.10. Surge in strategic partnerships between CROs and pharma companies for FSGS clinical trial optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Focal Segmental Glomerulosclerosis Market, by Drug Class

  • 8.1. Angiotensin Enzyme Inhibitors
  • 8.2. Angiotensin Receptor Blockers
  • 8.3. Corticosteroids

9. Focal Segmental Glomerulosclerosis Market, by Stage

  • 9.1. Primary
  • 9.2. Secondary

10. Focal Segmental Glomerulosclerosis Market, by End-Use

  • 10.1. Clinics
  • 10.2. Hospitals

11. Focal Segmental Glomerulosclerosis Market, by Patient Type

  • 11.1. Adults
  • 11.2. Pediatric

12. Focal Segmental Glomerulosclerosis Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Focal Segmental Glomerulosclerosis Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Focal Segmental Glomerulosclerosis Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Alkem Laboratories Ltd.
    • 15.3.2. Bristol Myers Squibb Company
    • 15.3.3. Certa Therapeutics Pty Ltd.
    • 15.3.4. Cipla Ltd.
    • 15.3.5. CMG Biotech Pvt. Ltd.
    • 15.3.6. Dr Reddy's Laboratories Ltd.
    • 15.3.7. Fresenius Kabi Pvt. Ltd.
    • 15.3.8. GSK PLC
    • 15.3.9. Hikma Pharmaceuticals PLC
    • 15.3.10. Intas Pharmaceuticals Ltd.
    • 15.3.11. Lupin Ltd.
    • 15.3.12. Merck & Co., Inc.
    • 15.3.13. Novartis AG
    • 15.3.14. Otsuka Pharmaceutical Co., Ltd
    • 15.3.15. Pfizer, Inc.
    • 15.3.16. Sanofi S.A.
    • 15.3.17. Travere Therapeutics, Inc.
    • 15.3.18. Vera Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN ENZYME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PRIMARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SECONDARY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 71. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 72. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. LATIN AMERICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 113. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 115. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 117. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 122. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 124. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 126. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. MIDDLE EAST FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 132. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 133. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 134. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 135. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 136. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 137. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. AFRICA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 154. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 155. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 156. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 157. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 158. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 159. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. ASEAN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 166. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 167. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 168. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 169. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. GCC FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPEAN UNION FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 184. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 185. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 186. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 187. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 188. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 189. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. BRICS FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 196. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 197. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 198. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 199. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. G7 FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 204. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 205. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 206. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 207. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 208. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 209. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. NATO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 219. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. UNITED STATES FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 225. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 227. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 231. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 233. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 235. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 240. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 241. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 242. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 243. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. BRAZIL FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 256. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 257. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 258. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 259. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. GERMANY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 262. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 263. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 265. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 266. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 267. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. FRANCE FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 270. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 271. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 272. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 273. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 274. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 275. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. RUSSIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 280. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 281. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 282. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 283. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ITALY FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 287. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 289. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 291. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. SPAIN FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 296. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 297. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 298. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2025-2032 (USD MILLION)
  • TABLE 299. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. CHINA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2018-2024 (USD MILLION)
  • TABLE 304. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY STAGE, 2025-2032 (USD MILLION)
  • TABLE 305. INDIA FOCAL SEGMENTAL GLOMERULOSCLEROSIS MARKET SIZE, BY END-USE, 2018-2024 (USD MILLION)
  • TABLE 306. INDIA FOCAL SEGMENTAL GLOMERULOSCLE